NasdaqGS - Delayed Quote • USD
Solid Biosciences Inc. (SLDB)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:01 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 8 | 8 | 7 | 7 |
Avg. Estimate | -0.64 | -0.64 | -2.66 | -2.77 |
Low Estimate | -1.09 | -1.13 | -3.73 | -3.76 |
High Estimate | -0.52 | -0.39 | -2.03 | -1.8 |
Year Ago EPS | -1.5 | -1.25 | -4.83 | -2.66 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 7 | 7 |
Avg. Estimate | 1.21M | 1.21M | 4.14M | 4.67M |
Low Estimate | -- | -- | -- | -- |
High Estimate | 4.4M | 4.4M | 17.6M | 17.7M |
Year Ago Sales | -- | -- | -- | 4.14M |
Sales Growth (year/est) | -- | -- | -- | 12.80% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -2.05 | -1.53 | -1.19 | -0.99 |
EPS Actual | -1.5 | -1.25 | -1.05 | -1 |
Difference | 0.55 | 0.28 | 0.14 | -0.01 |
Surprise % | 26.80% | 18.30% | 11.80% | -1.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.64 | -0.64 | -2.66 | -2.77 |
7 Days Ago | -0.64 | -0.64 | -2.66 | -2.77 |
30 Days Ago | -0.66 | -0.65 | -2.74 | -2.7 |
60 Days Ago | -0.99 | -1.02 | -3.34 | -2.54 |
90 Days Ago | -0.99 | -1.02 | -3.34 | -2.54 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | SLDB | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 57.30% | -- | -- | 5.40% |
Next Qtr. | 48.80% | -- | -- | 10.90% |
Current Year | 44.90% | -- | -- | 4.50% |
Next Year | -4.10% | -- | -- | 13.10% |
Next 5 Years (per annum) | -- | -- | -- | 10.94% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Initiated | William Blair: Outperform | 3/28/2024 |
Maintains | Barclays: Overweight to Overweight | 3/18/2024 |
Initiated | Citigroup: Buy | 3/15/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/14/2024 |
Upgrade | Piper Sandler: Neutral to Overweight | 3/14/2024 |
Maintains | HC Wainwright & Co.: Buy to Buy | 3/11/2024 |
Related Tickers
VYGR Voyager Therapeutics, Inc.
7.62
+2.70%
RGNX REGENXBIO Inc.
16.19
+0.81%
APRE Aprea Therapeutics, Inc.
5.20
-2.07%
ATXS Astria Therapeutics, Inc.
9.00
-1.85%
PASG Passage Bio, Inc.
1.3200
+8.20%
AVRO AVROBIO, Inc.
1.2100
+2.11%
DNTH Dianthus Therapeutics, Inc.
21.50
+2.43%
QURE uniQure N.V.
4.5300
-0.22%
DTIL Precision BioSciences, Inc.
9.38
-3.50%
PTCT PTC Therapeutics, Inc.
28.57
+12.08%